Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Trontinemab · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Trontinemab | EXPERIMENTAL | Participants will receive intravenous (IV) trontinemab. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive IV placebo. |
| Name | Type | Description |
|---|---|---|
| Trontinemab | DRUG | Participants will receive IV trontinemab. |
| Placebo | DRUG | Participants will receive IV placebo. |
Inclusion Criteria: * Body weight of 150 kg or less * Willingness and ability to complete all aspects of the study for the duration of the study * Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are ...
Top 20 of 24 competitors
Trontinemab is an investigational antibody being developed for Alzheimer's disease. It is studied in participants with early symptomatic Alzheimer's disease and in cognitively unimpaired individuals at risk for progression to symptomatic Alzheimer's disease. The drug is in Phase 3 clinical development.
Trontinemab is a monoclonal antibody, indicated by the '-mab' suffix in its name. It is being studied for its effects in Alzheimer's disease, a neurological condition. The specific molecular target of Trontinemab is not disclosed in the available clinical trial information.
Trontinemab is being developed by Roche Holding AG, a company traded under the ticker RHHBY. Roche is conducting Phase 3 clinical trials to evaluate the drug in Alzheimer's disease populations.
Trontinemab is in Phase 3 clinical development. There are multiple Phase 3 trials listed as recruiting or not yet recruiting. Trontinemab is investigational and has not been approved by regulatory authorities.
Trontinemab is being studied in three Phase 3 trials. NCT07169578 and NCT07170150 are recruiting participants with early symptomatic Alzheimer's disease, each with 800 participants. NCT07717411 is not yet recruiting and targets cognitively unimpaired individuals at risk for Alzheimer's disease, with 1,600 participants.
Trontinemab is a distinct monoclonal antibody developed by Roche. It is not identified as being the same as any other named drug in the available information. Its development program focuses on early symptomatic Alzheimer's disease and prevention in at-risk individuals.